EntrepreneurialCheck
Andrew Kruegel estimated net worth profile

Andrew Kruegel net worth

Andrew Kruegel Net Worth 2026 (Estimated) · Founder at Gilgamesh Pharmaceuticals · YC S20
est. wealth $56.0M

Quick answer

Andrew Kruegel's estimated net worth is $56.0M (range $39.2M – $84.0M) as of 2026. Andrew Kruegel is Founder at Gilgamesh Pharmaceuticals. Gilgamesh Pharmaceuticals valuation.

Andrew Kruegel is Founder at Gilgamesh Pharmaceuticals (YC S20). Independent Entrepreneurial Check model estimate from public YC data.

At a glance

NameAndrew Kruegel
RoleFounder
CompanyGilgamesh Pharmaceuticals
YC batchS20
Est. company val$600.0M
Assumed ownership9.3%
Est. paper wealth / net worth$56.0M
$39.2M – $84.0M
  • Company status: Active
  • Education: Ph.D. in Chemistry from Stanford University
  • Region: United States of America
  • Industries: Healthcare, Drug Discovery and Delivery
  • Team size: 15
  • Website: https://www.gilgameshpharmaceutical.com

Who is Andrew Kruegel?

Andrew Kruegel is a co-founder of Gilgamesh Pharmaceuticals, which focuses on developing novel therapeutics inspired by the power of plant biology.

Highlights:

  • Stanford University
  • Harvard University
  • Y Combinator S20

About Gilgamesh Pharmaceuticals

Gilgamesh is a pioneering, clinical stage mental health science-focused biotechnology company. We have a disciplined focus on developing innovative new chemical entities (NCEs) leveraging a unique combination of medicinal chemistry, intellectual property strategy, neuroscience & neurobiology, and drug development expertise. We are an experienced team, with proven success in biotech exits and inventions.

FAQ: Andrew Kruegel net worth and Gilgamesh Pharmaceuticals valuation

What is Andrew Kruegel's net worth?

Andrew Kruegel's estimated net worth is $56.0M (range $39.2M – $84.0M) as of 2026. Andrew Kruegel is Founder at Gilgamesh Pharmaceuticals. Entrepreneurial Check publishes an independent model-based estimate from public company and role data. Not verified net worth, and Entrepreneurial Check is not affiliated with Y Combinator or the profiled companies.

What is Gilgamesh Pharmaceuticals valuation?

Gilgamesh Pharmaceuticals's estimated valuation on Entrepreneurial Check is $600.0M. That valuation, or a disclosed round when one is public, is the source for the paper-wealth estimate. Independent model output — not a verified appraisal or official mark.

What is Andrew Kruegel's role?

Andrew Kruegel is Founder at Gilgamesh Pharmaceuticals, a Y Combinator-backed startup (batch S20).